References
- Saeedi P, Salpea P, Karuranga S., et al. Mortality attributable to diabetes in 20-79 years old adults, 2019 estimates: results from the International Diabetes Federation Diabetes Atlas, 9 edition. Diabetes Res Clin Pract. 2020;162:108086.
- Rivera-Mancía S, Lozada-García M, Pedraza-Chaverri J. Experimental evidence for curcumin and its analogs for management of diabetes mellitus and its associated complications. Eur J Pharmacol. 2015;756:30–37.
- Neish A. Microbes in gastrointestinal health and disease. Gastroenterology. 2009;136(1):65–80.
- Zheng P, Zeng B, Zhou C, et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism. Mol Psychiatry. 2016;21(6):786–796.
- Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65.
- Wu X, Ma C, Han L, et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol. 2010;61(1):69–78.
- Ortega M, Fraile-Martínez O, Naya I, et al. Type 2 Diabetes Mellitus Associated with Obesity (Diabesity). The Central Role of Gut Microbiota and Its Translational Applications. Nutrients. 2020;12(9):654.
- Tanase D, Gosav E, Neculae E, et al. Role of Gut Microbiota on Onset and Progression of Microvascular Complications of Type 2 Diabetes (T2DM). Nutrients. 2020;12:12.
- Chávez-Carbajal A, Pizano-Zárate M, Hernández-Quiroz F, et al. Characterization of the Gut Microbiota of Individuals at Different T2D Stages Reveals a Complex Relationship with the Host. Microorganisms. 2020;8(1):548.
- Huda M, Kim M, Bennett B. Modulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes. Front Endocrinol (Lausanne). 2021;12:632335.
- Zhang Q, Hu N. Effects of Metformin on the Gut Microbiota in Obesity and Type 2 Diabetes Mellitus. Diabetes Metabolic Syndrome Obesity. 2020;13:5003–5014.
- Pasini E, Corsetti G, Assanelli D, et al. Effects of chronic exercise on gut microbiota and intestinal barrier in human with type 2 diabetes. Minerva Med. 2019;110(1):3–11.
- Nascimento J, Matheus V, Oliveira R, Tada S, Collares-Buzato C. High-Fat Diet Induces Disruption of the Tight Junction-Mediated Paracellular Barrier in the Proximal Small Intestine Before the Onset of Type 2 Diabetes and Endotoxemia. Dig Dis Sci. 2021;66(10):3359–3374.
- Wu W, Liu L, Zhu H, et al. Butyrolactone-I, an efficient α-glucosidase inhibitor, improves type 2 diabetes with potent TNF-α-lowering properties through modulating gut microbiota in db/db mice. FASEB j. 2019;33(11):12616–12629.
- Cani P, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470–1481.
- Cani P, Amar J, Iglesias M, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–1772.
- Pang B, Lian F, Zhao X, et al. Prevention of type 2 diabetes with the traditional Chinese patent medicine: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2017;131:242–259.
- Tilg H, Moschen A. Microbiota and diabetes: an evolving relationship. Gut. 2014;63(9):1513–1521.
- Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care. 2012;35(11):2121–2127.
- Zhang R, Zhou J, Jia Z, Zhang Y, Gu G. Hypoglycemic effect of Rehmannia glutinosa oligosaccharide in hyperglycemic and alloxan-induced diabetic rats and its mechanism. J Ethnopharmacol. 2004;90(1):39–43.
- Mendes J, Leandro C, Bonaparte D, Pinto A. A rat model of diabetic wound infection for the evaluation of topical antimicrobial therapies. Comp Med. 2012;62(1):37–48.
- Yan H, Lu J, Wang Y, Gu W, Yang X, Yu J. Intake of total saponins and polysaccharides from Polygonatum kingianum affects the gut microbiota in diabetic rats. Phytomedicine. 2017;26:45–54.
- Chen M, Liao Z, Lu B, et al. Huang-Lian-Jie-Du-Decoction Ameliorates Hyperglycemia and Insulin Resistant in Association With Gut Microbiota Modulation. Front Microbiol. 2018;9:2380.
- Callahan B, McMurdie P, Rosen M, Han A, Johnson A, Holmes S. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13(7):581–583.
- Callahan B, Wong J, Heiner C, et al. High-throughput amplicon sequencing of the full-length 16S rRNA gene with single-nucleotide resolution. Nucleic Acids Res. 2019;47(18):e103.
- Amir A, McDonald D, Navas-Molina J, et al. Deblur Rapidly Resolves Single-Nucleotide Community Sequence Patterns. mSystems. 2017;2:2.
- Hagan T, Cortese M, Rouphael N, et al. Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans. Cell. 2019;178(6):1313–1328.e1313.
- Vallianou N, Stratigou T, Tsagarakis S. Microbiome and diabetes: where are we now? Diabetes Res Clin Pract. 2018;146:111–118.
- Sedighi M, Razavi S, Navab-Moghadam F, et al. Comparison of gut microbiota in adult patients with type 2 diabetes and healthy individuals. Microb Pathog. 2017;111:362–369.
- Fassatoui M, Lopez-Siles M, Díaz-Rizzolo D, et al. Gut microbiota imbalances in Tunisian participants with type 1 and type 2 diabetes mellitus. Biosci Rep. 2019;39:6.
- Halawa M, El-Salam M, Mostafa B, Sallout S. The Gut Microbiome, Lactobacillus acidophilus; Relation with Type 2 Diabetes Mellitus. Curr Diabetes Rev. 2019;15(6):480–485.
- Chen P, Chien Y, Yang S. The alteration of gut microbiota in newly diagnosed type 2 diabetic patients. Nutrition. 2019;1:51–56.
- Zhang P, Li L, Han X, et al. Fecal microbiota transplantation improves metabolism and gut microbiome composition in db/db mice. Acta Pharmacol Sin. 2020;41(5):678–685.
- Joyce S, Gahan C. Disease-Associated Changes in Bile Acid Profiles and Links to Altered Gut Microbiota. Digestive Dis. 2017;35(3):169–177.
- Gong P, Xiao X, Wang S, et al. Hypoglycemic effect of astragaloside IV via modulating gut microbiota and regulating AMPK/SIRT1 and PI3K/AKT pathway. J Ethnopharmacol. 2021;281:114558.
- Zhang S, Zhang N, Guo S, et al. Pueraria thomsoniiGlycosides and flavonoids from the extract of Benth leaf alleviate type 2 diabetes in high-fat diet plus streptozotocin-induced mice by modulating the gut microbiota. Food Funct. 2022;13(7):3931–3945.
- Guo C, Wang Y, Zhang S, et al. Crataegus pinnatifida polysaccharide alleviates colitis via modulation of gut microbiota and SCFAs metabolism. Int J Biol Macromol. 2021;181:357–368.
- Zhai Z, Niu K, Liu Y, Lin C, Wu X. Eucommia ulmoidesThe Gut Microbiota-Bile Acids-TGR5 Axis Mediates Leaf Extract Alleviation of Injury to Colonic Epithelium Integrity. Front Microbiol. 2021;12:727681.
- Zhang W, Xu J, Yu T, Chen Q. Effects of berberine and metformin on intestinal inflammation and gut microbiome composition in db/db mice. Biomed Pharmacother. 2019;118:109131.
- Cheung S, Goldenthal A, Uhlemann A, Mann J, Miller J, Sublette M. Systematic Review of Gut Microbiota and Major Depression. Front Psychiatry. 2019;10:34.
- Jasirwan C, Muradi A, Hasan I, Simadibrata M, Rinaldi I. Correlation of gut Firmicutes/Bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease. Biosci Microbiota Food Health. 2021;40(1):50–58.
- Xia F, Wen L, Ge B, Li Y, Li F, Zhou B. Gut microbiota as a target for prevention and treatment of type 2 diabetes: mechanisms and dietary natural products. World J Diabetes. 2021;12(8):1146–1163.
- Everard A, Cani P. Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol. 2013;27(1):73–83.
- Stojanov S, Berlec A, Štrukelj B. The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease. Microorganisms. 2020;8:11.
- Qiao S, Bao L, Wang K, et al. Activation of a Specific Gut Bacteroides-Folate-Liver Axis Benefits for the Alleviation of Nonalcoholic Hepatic Steatosis. Cell Rep. 2020;32(6):108005.
- Liu J, Segovia I, Yuan X, Gao Z. Controversial Roles of Gut Microbiota-Derived Short-Chain Fatty Acids (SCFAs) on Pancreatic β-Cell Growth and Insulin Secretion. Int J Mol Sci. 2020;21(3):215.
- Wei W, Jiang W, Tian Z, et al. Fecal g. Streptococcus and g. Eubacterium_coprostanoligenes_group combined with sphingosine to modulate the serum dyslipidemia in high-fat diet mice. Clinical Nutrition. 2021;40(6):4234–4245.
- Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60.
- Wang J, Bose S, Shin N, Chin Y, Choi Y, Kim H. Houttuynia CordataPharmaceutical Impact of and Metformin Combination on High-Fat-Diet-Induced Metabolic Disorders: link to Intestinal Microbiota and Metabolic Endotoxemia. Front Endocrinol (Lausanne). 2018;9:620.
- Wang C, Xiao Y, Yu L, et al. Bacteroides vulgatusProtective effects of different strains against lipopolysaccharide-induced acute intestinal injury, and their underlying functional genes. J Adv Res. 2022;36:27–37.
- Lee J, Kwon S, Han J, Cho S, Cho Y, Park J. A mucin-responsive hybrid two-component system controls Bacteroides thetaiotaomicron colonization and gut homeostasis. J Microbiol. 2022;60(2):215–223.
- Brahe L, Le Chatelier E, Prifti E, et al. Specific gut microbiota features and metabolic markers in postmenopausal women with obesity. Nutr Diabetes. 2015;5:e159.
- Shin N, Lee J, Lee H, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 2014;63(5):727–735.
- Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25(7):1096–1103.
- Derrien M, Vaughan E, Plugge C, de Vos W. Akkermansia muciniphila gen. Int j Sys Evolutionary Microbiol. 2004;54:1469–1476.
- Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013;110(22):9066–9071.
- Kong W, Zhang H, Song D, et al. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism. 2009;58(1):109–119.
- Fedorak R, Vanner S, Paterson W, Bridges R. Canadian Digestive Health Foundation Public Impact Series 3: irritable bowel syndrome in Canada. J canadien de gastroenterol. 2012;26(5):252–256.
- Shi X, Wang S, Luan H, et al. Clinopodium chinense Attenuates Palmitic Acid-Induced Vascular Endothelial Inflammation and Insulin Resistance through TLR4-Mediated NF- B and MAPK Pathways. Am J Chin Med. 2019;47(1):97–117.
- Pahlavani M, Ramalho T, Koboziev I, et al. Adipose tissue inflammation in insulin resistance: review of mechanisms mediating anti-inflammatory effects of omega-3 polyunsaturated fatty acids. J Investigative Med. 2017;65(7):1021–1027.
- Higuchi I, Kimura Y, Kobayashi M, et al. Relationships between plasma lactate, plasma alanine, genetic variations in lactate transporters and type 2 diabetes in the Japanese population. Drug Metab Pharmacokinet. 2020;35(1):131–138.
- Dibe H, Townsend L, McKie G, Wright D. Epinephrine responsiveness is reduced in livers from trained mice. Physiol Rep. 2020;8(3):e14370.
- Zhu Y, Qian X, Li J, et al. Astragaloside-IV protects H9C2 (2-1)cardiomyocytes from high glucose-induced injury via miR-34a-mediated autophagy pathway. Artif Cells, Nanomed Biotechnol. 2019;47(1):4172–4181.
- Chen X, Han Y, Wang H. Relations of hepatic steatosis with liver functions, inflammations, glucolipid metabolism in chronic hepatitis B patients. Eur Rev Med Pharmacol Sci. 2018;22(17):5640–5646.
- Wolf P, Winhofer Y, Anderwald C, Krå¡å¡ã¡k M, Krebs M. Intracellular lipid accumulation and shift during diabetes progression. Wiener medizinische Wochenschrift. 2014;164:320–329.
- Huang S, Peng W, Jiang X, et al. The effect of chromium picolinate supplementation on the pancreas and macroangiopathy in type II diabetes mellitus rats. J Diabetes Res. 2014;2014:717219.
- Fan Y, He Z, Wang W, et al. Tangganjian decoction ameliorates type 2 diabetes mellitus and nonalcoholic fatty liver disease in rats by activating the IRS/PI3K/AKT signaling pathway. Biomed Pharmacother. 2018;106:733–737.
- Baek S, Kim K, Kim S, Son Y, Hong H, Yu S. SP prevents T2DM complications by immunomodulation. Sci Rep. 2020;10(1):16753.
- Senn J, Klover P, Nowak I, Mooney R. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 2002;51(12):3391–3399.
- Yang C, Luo S, Hsieh H, et al. Interleukin-1beta induces ICAM-1 expression enhancing leukocyte adhesion in human rheumatoid arthritis synovial fibroblasts: involvement of ERK, JNK, AP-1, and NF-kappaB. J Cell Physiol. 2010;224(2):516–526.
- Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003;278(46):45777–45784.